The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

MARK3  -  MAP/microtubule affinity-regulating kinase 3

Homo sapiens

Synonyms: C-TAK1, CTAK1, Cdc25C-associated protein kinase 1, ELKL motif kinase 2, EMK-2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MARK3


Psychiatry related information on MARK3


High impact information on MARK3

  • C-TAK1 constitutively associates with mammalian KSR1 and phosphorylates serine 392 to confer 14-3-3 binding and cytoplasmic sequestration of KSR1 in unstimulated cells [8].
  • Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate [9].
  • Here, we identify sequence motifs required for stable C-TAK1 association and substrate phosphorylation [9].
  • New Role for hPar-1 Kinases EMK and C-TAK1 in Regulating Localization and Activity of Class IIa Histone Deacetylases [10].
  • High concentrations of UCN-01 caused rapid activation of Cdc25C, which is attributed to inhibition of C-TAK1, as well as Chk1/2 [11].

Biological context of MARK3

  • We demonstrate that 14-3-3 binding to MARK3 is dependent on phosphorylation, and necessitates the phosphate-binding pocket of 14-3-3 [12].
  • The transcript expressed in liver consisted of 3529 nucleotides that contained an open reading frame of 2256 nucleotides, encoding 752 amino acids homologous to human MARK3 (MAP/microtubule affinity-regulating kinase 3) [13].
  • Cdc25C-associated kinase 1 (C-TAK1) has been implicated in cell cycle regulation and Ras signaling through its interactions with two putative substrates, the Cdc25C phosphatase and the MAPK scaffold KSR1 [9].
  • C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding [14].
  • C-TAK1 is ubiquitously expressed in human tissues and cell lines and is distinct from the DNA damage checkpoint kinase Chk1, shown previously to phosphorylate Cdc25C on serine 216 [14].

Anatomical context of MARK3


Associations of MARK3 with chemical compounds

  • Taken together, these results suggest that one function of C-TAK1 may be to regulate the interactions between Cdc25C and 14-3-3 in vivo by phosphorylating Cdc25C on serine 216 [14].
  • The halothane Cyprane (Fluotec) Mark 3 and enflurane Cyprane vaporizers were largely independent of density [15].
  • Changes in lipid levels (high-density lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, very low density lipoprotein cholesterol, and triglycerides) were evaluated, and health-related quality of life was assessed based on scores on the Diabetes Care Profile (DCP) and Health Utilities Index Mark 3 (HU13) [16].
  • METHODS AND RESULTS: Forty-two patients who presented with a conventional indication for DDD pacing or cardiac resynchronization underwent conventional polysomnography 1 month after implantation of a Talent trade mark 3 pacemaker (ELA Medical) [17].

Regulatory relationships of MARK3

  • 9. In contrast, phenanthroline and apyrase significantly enhanced the anti-aggregatory effects of aspirin against thrombin-, PAR1AP- and TRAP-induced aggregation suggesting the involvement of ADP- and MMP-2-dependent pathways [18].
  • Binding of 14-3-3beta to PTPH1 in vitro was abolished by pretreating PTPH1 with potato acid phosphatase and was greatly enhanced by pretreating with Cdc25C-associated protein kinase [19].

Other interactions of MARK3

  • Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis [13].
  • 10. PAR4AP-induced aggregation (but not PAR1AP-induced aggregation) was entirely ADP-dependent (abolished by apyrase) and resistant to phenanthroline (MMP-2-independent) [18].
  • Homologous human platelet-leukocyte suspensions were stimulated with thrombin (0.1-3 nM) and other proteinase activated receptor-activating peptides (PAR-AP), including PAR1AP (0.5-10 microM), PAR4AP (10-70 microM), and thrombin receptor-activating peptide (1-35 microM) [20].
  • The reverse human PAR4 sequence (VQGPYG-NH2, YG-NH2) and the PAR1AP SFLLR-NH2, did not cause aggregation [21].
  • High concentrations of UCN-01 also inhibit C-TAK1 that results in S phase-arrested cells directly entering mitosis, but this property was not observed with ICP-1 [22].

Analytical, diagnostic and therapeutic context of MARK3

  • A physical interaction of Pim-1 and C-TAK1 could be shown biochemically and in yeast two-hybrid assays [23].
  • Assignment of MARK3 alias KP78 to human chromosome band 14q32.3 by in situ hybridization [24].
  • We examine the relationship between Visual Analogue Scale (VAS) and Standard Gamble (SG) assumed in the development of the multiplicative multi-attribute utility functions (M-MAUFs) for the Health Utilities Index (HUI) Mark 2 and Mark 3, using data from a UK valuation study of the HUI2 [25].
  • Patient-reported outcomes included changes in health-related quality of life (Health Utilities Index Mark 3 [HUI3]), satisfaction with care, lifestyle (Diabetes Lifestyle Form), and adherence to self-care activities [26].
  • METHODS: HRQoL data were obtained in two randomized, double-blind, placebo-controlled, multidose clinical trials conducted in the United States and Canada. The Health Utilities Index Mark 3 (HUI3) was administered in both studies at baseline, at the end of the study and at two time points in between [27].


  1. Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Spicer, J., Rayter, S., Young, N., Elliott, R., Ashworth, A., Smith, D. Oncogene (2003) [Pubmed]
  2. Is the Health Utilities Index responsive in total hip arthroplasty patients? Blanchard, C., Feeny, D., Mahon, J.L., Bourne, R., Rorabeck, C., Stitt, L., Webster-Bogaert, S. Journal of clinical epidemiology. (2003) [Pubmed]
  3. A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. Luo, N., Chew, L.H., Fong, K.Y., Koh, D.R., Ng, S.C., Yoon, K.H., Vasoo, S., Li, S.C., Thumboo, J. J. Rheumatol. (2003) [Pubmed]
  4. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication. Bosch, J.L., Hunink, M.G. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. (2000) [Pubmed]
  5. Evaluation and measurement of health-related quality of life for individuals with diabetes mellitus by Health Utilities Index Mark 3 (HUI3) system. Mo, F., Morrison, H., Choi, B.C., Vardy, L. ScientificWorldJournal (2006) [Pubmed]
  6. Mental health comorbidity patterns and impact on quality of life among veterans serving during the first Gulf War. Forman-Hoffman, V.L., Carney, C.P., Sampson, T.R., Peloso, P.M., Woolson, R.F., Black, D.W., Doebbeling, B.N. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. (2005) [Pubmed]
  7. Measuring patient quality of life: is the health utility index useful? Tempier, R., Pawliuk, N. The Psychiatric quarterly (2007) [Pubmed]
  8. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Müller, J., Ory, S., Copeland, T., Piwnica-Worms, H., Morrison, D.K. Mol. Cell (2001) [Pubmed]
  9. Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate. Müller, J., Ritt, D.A., Copeland, T.D., Morrison, D.K. EMBO J. (2003) [Pubmed]
  10. New Role for hPar-1 Kinases EMK and C-TAK1 in Regulating Localization and Activity of Class IIa Histone Deacetylases. Dequiedt, F., Martin, M., Von Blume, J., Vertommen, D., Lecomte, E., Mari, N., Heinen, M.F., Bachmann, M., Twizere, J.C., Huang, M.C., Rider, M.H., Piwnica-Worms, H., Seufferlein, T., Kettmann, R. Mol. Cell. Biol. (2006) [Pubmed]
  11. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. Kohn, E.A., Ruth, N.D., Brown, M.K., Livingstone, M., Eastman, A. J. Biol. Chem. (2002) [Pubmed]
  12. Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation. Göransson, O., Deak, M., Wullschleger, S., Morrice, N.A., Prescott, A.R., Alessi, D.R. J. Cell. Sci. (2006) [Pubmed]
  13. Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis. Kato, T., Satoh, S., Okabe, H., Kitahara, O., Ono, K., Kihara, C., Tanaka, T., Tsunoda, T., Yamaoka, Y., Nakamura, Y., Furukawa, Y. Neoplasia (2001) [Pubmed]
  14. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Peng, C.Y., Graves, P.R., Ogg, S., Thoma, R.S., Byrnes, M.J., Wu, Z., Stephenson, M.T., Piwnica-Worms, H. Cell Growth Differ. (1998) [Pubmed]
  15. An evaluation of gas density dependence of anaesthetic vaporizers. Prins, L., Strupat, J., Clement, J., Knill, R.L. Canadian Anaesthetists' Society journal. (1980) [Pubmed]
  16. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Roberts, V.L., Stewart, J., Issa, M., Lake, B., Melis, R. Clinical therapeutics. (2005) [Pubmed]
  17. Automatic recognition of abnormal respiratory events during sleep by a pacemaker transthoracic impedance sensor. Defaye, P., Pépin, J.L., Poezevara, Y., Mabo, P., Murgatroyd, F., Lévy, P., Garrigue, S. J. Cardiovasc. Electrophysiol. (2004) [Pubmed]
  18. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Chung, A.W., Jurasz, P., Hollenberg, M.D., Radomski, M.W. Br. J. Pharmacol. (2002) [Pubmed]
  19. Serine phosphorylation-dependent association of the band 4.1-related protein-tyrosine phosphatase PTPH1 with 14-3-3beta protein. Zhang, S.H., Kobayashi, R., Graves, P.R., Piwnica-Worms, H., Tonks, N.K. J. Biol. Chem. (1997) [Pubmed]
  20. Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Chung, A.W., Radomski, A., Alonso-Escolano, D., Jurasz, P., Stewart, M.W., Malinski, T., Radomski, M.W. Br. J. Pharmacol. (2004) [Pubmed]
  21. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Hollenberg, M.D., Saifeddine, M. Can. J. Physiol. Pharmacol. (2001) [Pubmed]
  22. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Eastman, A., Kohn, E.A., Brown, M.K., Rathman, J., Livingstone, M., Blank, D.H., Gribble, G.W. Mol. Cancer Ther. (2002) [Pubmed]
  23. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. Bachmann, M., Hennemann, H., Xing, P.X., Hoffmann, I., Möröy, T. J. Biol. Chem. (2004) [Pubmed]
  24. Assignment of MARK3 alias KP78 to human chromosome band 14q32.3 by in situ hybridization. Ono, T., Kawabe, T., Sonta, S., Okamoto, T. Cytogenet. Cell Genet. (1997) [Pubmed]
  25. Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey. Stevens, K.J., McCabe, C.J., Brazier, J.E. Health economics. (2006) [Pubmed]
  26. Improvements in patient-reported outcomes associated with an intervention to enhance quality of care for rural patients with type 2 diabetes: results of a controlled trial. Maddigan, S.L., Majumdar, S.R., Guirguis, L.M., Lewanczuk, R.Z., Lee, T.K., Toth, E.L., Johnson, J.A. Diabetes Care (2004) [Pubmed]
  27. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Torrance, G.W., Tugwell, P., Amorosi, S., Chartash, E., Sengupta, N. Rheumatology (Oxford, England) (2004) [Pubmed]
WikiGenes - Universities